扁平部
玻璃体切除术
重组组织纤溶酶原激活剂
医学
视网膜前膜
眼科
组织纤溶酶原激活剂
视网膜
玻璃体出血
视网膜脱离
外科
内科学
视力
缺血
缺血性中风
改良兰金量表
作者
Tingkun Shi,Jing Wen,Xia Hu,Haoyu Chen
出处
期刊:Retina-the Journal of Retinal and Vitreous Diseases
[Ovid Technologies (Wolters Kluwer)]
日期:2024-03-06
标识
DOI:10.1097/iae.0000000000004093
摘要
To evaluate the outcomes and prognostic factors of pars plana vitrectomy (PPV) combined with subretinal injection of recombinant tissue plasminogen activator (rt-PA) for submacular hemorrhage (SMH) patients with or without vitreous hemorrhage.Sixty-four eyes of 64 patients with SMH patients underwent PPV with subretinal injection of rt-PA. Best-corrected visual acuity (BCVA), SMH displacement, and postoperative complications were analyzed. Predictive factors of the final BCVA were determined using multivariant linear regression.There were 26 eyes with VH and 38 without VH BCVA significantly improved in both VH group (from 2.27±0.40 to 1.25±0.70 LogMAR) and non-VH group (from 1.76±0.55 to 0.85±0.65 LogMAR). Completely displacement of SMHs was observed in 47 (73.43%) eyes. Postoperative complications included recurrent SMH (4.69%), recurrent vitreous hemorrhage (10.94%), rhegmatogenous retinal detachment (3.13%), and epiretinal membrane (4.68%). Treatment-naive condition, early surgery, and younger age were significantly associated with better final BCVA (B =0.502, 0.303, and 0.021, respectively, with all p <0.05).PPV combined with subretinal rt-PA injection is an effective treatment for SMH patients with and without VH.
科研通智能强力驱动
Strongly Powered by AbleSci AI